# A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants

> **NCT05458076** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 86 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** QLS1128 A-Dose 1~5 and Ritonavir
- **DRUG:** QLS1128 C-Dose 1~3 and Ritonavir
- **DRUG:** QLS1128 D-Dose 1 and Ritonavir

## Key facts

- **NCT ID:** NCT05458076
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-03
- **Primary completion:** 2022-09-06
- **Final completion:** 2022-09-06
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05458076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05458076, "A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05458076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*